RxSight, Inc. (RXST) stock
RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3076% below fair value
$4.83−0.47 (-8.87%)
Close on Nov 17, 2026Market cap $200.90MP/E –Yield –
RxSight operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
RxSight's operating income for the twelve months ending Jun 30, 2026 was -$55.11M. For fiscal 2025 it was -$48.19M. The highest annual figure on record is -$35.41M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.19M | – |
| FY2024 | Dec 31, 2024 | -$36.86M | – |
| FY2023 | Dec 31, 2023 | -$50.09M | – |
| FY2022 | Dec 31, 2022 | -$63.32M | – |
| FY2021 | Dec 31, 2021 | -$52.79M | – |
| FY2020 | Dec 31, 2020 | -$35.41M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$13.77M | – |
| Q1 FY2026 | Mar 31, 2026 | -$17.83M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.34M | – |
| Q3 FY2025 | Sep 30, 2025 | -$12.18M | – |
| Q2 FY2025 | Jun 30, 2025 | -$14.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.67M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.23M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.67M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.85M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.51M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.10M | – |
| Q4 FY2022 | Dec 31, 2022 | -$14.99M | – |
| Q3 FY2022 | Sep 30, 2022 | -$15.96M | – |
| Q2 FY2022 | Jun 30, 2022 | -$15.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$16.58M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.66M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.11M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.88M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.30M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.91M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.81M | – |
See a number that looks wrong?